Welcome to the Nature Biotechnology and Nature Reviews Drug Discovery joint Web Focus on Antibacterials.
This Web Focus, supported by AstraZeneca and Wyeth Pharmaceuticals, hosts a collection of News and Views, Research Highlights, Reviews, Research Articles, Perspectives and Commentaries covering the science and business of antibacterial drug R&D. It also includes an online-only NPG library of recent research papers and review content from other NPG journals.
Editorials
Bring the magic back to the bullets
doi:10.1038/nbt1206-1489
Nature Biotechnology 24, 2 (2006)
The end of an era?
doi:10.1038/nrd2223
Nature Reviews Drug Discovery 6, 1 (2007)
News & Analysis
The antibacterial drugs market
doi:10.1038/nrd2226
Nature Reviews Drug Discovery 6, 1 (2007)
News Features
Anti-infective antibodies: finding the path forward
Monya Baker
doi:10.1038/nbt1206-1491
Nature Biotechnology 24, 2 (2006)
Antibiotics au naturel
Cormac Sheridan
doi:10.1038/nbt1206-1494
Nature Biotechnology 24, 2 (2006)
Commentaries
Prospects for plant-derived antibacterials
Kim Lewis and Frederick M Ausubel
doi:10.1038/nbt1206-1504
Nature Biotechnology 24, 2 (2006)
Antibiotics an investment worth making?
Ralph E Christoffersen
doi:10.1038/nbt1206-1512
Nature Biotechnology 24, 2 (2006)
Reinventing phage therapy: are the parts greater than the sum?
Vincent A Fischetti, Daniel Nelson and Raymond Schuch
doi:10.1038/nbt1206-1508
Nature Biotechnology 24, 2 (2006)
Moving goalposts - regulatory oversight of antibacterial drugs
Randall Brenner, Evelyn Ellis Grosse and Roger Echols
doi:10.1038/nbt1206-1515
Nature Biotechnology 24, 2 (2006)
Antibacterial discovery and development - the failure of success?
Prabhavathi Fernandes
doi:10.1038/nbt1206-1497
Nature Biotechnology 24, 2 (2006)
Features
The business of developing antibacterials
Jeffrey L Fox
doi:10.1038/nbt1206-1521
Nature Biotechnology 24, 2 (2006)
Where have all the antibiotic patents gone?
Martin L Katz, Lisa V Mueller, Mark Polyakov and Steven F Weinstock
doi:10.1038/nbt1206-1529
Nature Biotechnology 24, 2 (2006)
Research Highlights
Riboswitching off bacterial growth
Joanna Owens
doi:10.1038/nrd2235
Nature Reviews Drug Discovery 6, 1 (2007)
Reviews
Drugs for bad bugs: confronting the challenges of antibacterial drug discovery
David J. Payne, Michael N. Gwynn, David J. Holmes and David L. Pompliano
doi:10.1038/nrd2201
Nature Reviews Drug Discovery advance online publication, 8 December 2006
Multi-targeting by monotherapeutic antibacterials
Lynn L. Silver
doi:10.1038/nrd2202
Nature Reviews Drug Discovery advance online publication, 8 December 2006
Waltzing transporters and 'the dance macabre' between humans and bacteria
Olga Lomovskaya, Helen I. Zgurskaya, Maxim Totrov and William J. Watkins
doi:10.1038/nrd2200
Nature Reviews Drug Discovery advance online publication, 8 December 2006
Molecular engineering approaches to peptide, polyketide and other antibiotics
Richard H Baltz
doi:10.1038/nbt1265
Nature Biotechnology 24, 813-819 (2006)
New antibiotics from bacterial natural products
Jon Clardy, Michael A Fischbach and Christopher T Walsh
doi:10.1038/nbt1266
Nature Biotechnology 24, 820-828 (2006)
Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies
Robert E W Hancock and Hans-Georg Sahl
doi:10.1038/nbt1267
Nature Biotechnology 24, 820-828 (2006)
Riboswitches as antibacterial drug targets
Kenneth F Blount and Ronald R Breaker
doi:10.1038/nbt1268
Nature Biotechnology 24, 820-828 (2006)